Immune Response BioPharma Reports 2nd Half 2011 Results

January 2nd, 2012 -- Immune Response BioPharma, Inc. had a strong 2nd Half of 2011 demonstrating its strong technology and intellectual property position by licensing a key auto immune disease patent, appointing three new directors to our board and filling key management positions.

IRBP 2nd Half 2011 Highlights

• Appointed Three New Directors to the Board of Directors including

• Dr. Ronald Moss joins IRBP board and brings a wealth of clinical development experience and management to IRBP.

• Dr. Richard Bartholomew joins the board and assumes the position of Chief R&D Officer he brings a strong background of R&D to IRBP and will handle manufacturing duties for our world class MS drug NeuroVax.

• Dr. Arthur Vandenbark joins the board and is the primary inventor of NeuroVax will lead the way for our clinical pipeline as our Chief Scientific Officer.

• IRBP Licenses Key Auto Immune Diseases Patent U.S. 8,053,197 for the Treatment of Auto Immune Diseases and Methods and Obtains the FOXP3+ Expression Technology in an Exclusive License from OHSU Oregon Health & Science University, The IP Extends out to 2027.

• Declared 5000 for 1 Stock Split and increases authorized share count to 15,000,000 shares.

“This has been an exciting year for IRBP and we achieved the majority of our goals as we continue to ramp up the company for long term success. We licensed key technology FOXP3+ Expression technology for auto immune diseases and added key executives for our board of directors and filled key management positions. I am proud of our team and look forward to building our company into a world class biopharmaceutical company to help treat unmet diseases with our world class technology and clinical pipeline” IRBP COO Mr. Buswell.

2012 First Half Guidance

• Capitalize the Company

• Fill the Chief Executive Officer Position

• File Open IND’s for NeuroVax and REMUNE & Seek Approval for a Phase 2B 200 Patient Clinical Trial for NeuroVax

• File Orphan Designation for NeuroVax and REMUNE

• Meet with the FDA & South African Government Officials to Discuss Emergency Approval of REMUNE

“Looking forward we have a lot of work yet to do but I am confident we will achieve our goals of developing vaccine treatments NeuroVax for MS and REMUNE for HIV/AIDS. At some point you have to realize throwing toxic drugs at patients infected with HIV is a losing cause and go back to what works a whole killed vaccine approach as patients with multi drug resistance would benefit from REMUNE greatly, transitioning REMUNE to a preventative vaccine approach in South Africa makes a lot of sense where the risk to reward ratio is more favorable. The role and opportunity for REMUNE has only gotten bigger as the disease is rapidly expanding” Mr. Buswell COO IRBP.

Forward Looking Statements

Plans to raise capital is neither an offer nor solicitation for sale of securities. Forward looking statements are based upon future projections, timeframes and current information and IRBP makes no guarantee that its products will be successful or approved in a highly regulated market. Clinical trials and data may not be sufficient to satisfy regulatory requirements.

Immune Response BioPharma may be found on the world wide web at www.immuneresponsebiopharma.com

Back to news